Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles European Journal of Heart Failure Year : 2021

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society

1 Imperial College London
2 Duke University [Durham]
3 The Royal Marsden
4 CAM - University of Cambridge [UK]
5 MSH - Mount Sinai Hospital [Toronto, Canada]
6 MASCOT (UMR_S_942 / U942) - Marqueurs cardiovasculaires en situation de stress
7 Hôpital Lariboisière-Fernand-Widal [APHP]
8 University of Naples Federico II = Università degli studi di Napoli Federico II
9 Vanderbilt University Medical Center [Nashville]
10 BWH - Brigham & Women’s Hospital [Boston]
11 Medizinische Universität Wien = Medical University of Vienna
12 Monash University [Melbourne]
13 PSC - Shanghai Center for Plant Stress Biology [CAS]
14 DZHK - German Center for Cardiovascular Research
15 Georg-August-University = Georg-August-Universität Göttingen
16 MHH - Medizinische Hochschule Hannover = Hannover Medical School
17 UK - Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic]
18 GU - Georgetown University [Washington]
19 University Health Network [Toronto, ON, Canada]
20 University of Toronto
21 University of Pennsylvania
22 Massachusetts General Hospital [Boston]
23 Sechenov First Moscow State Medical University
24 UCL - University College of London [London]
25 TAU - Tel Aviv University
26 UoN - University of Newcastle [Callaghan, Australia]
27 USP - Universidade de São Paulo = University of São Paulo
28 Università degli studi della Campania "Luigi Vanvitelli" = University of the Study of Campania Luigi Vanvitelli
29 UCY - University of Cyprus [Nicosia]
30 UMCG - University Medical Center Groningen [Groningen]
31 AUB - American University of Beirut Faculty of Medicine and Medical Center
32 UNIBE - Universität Bern / University of Bern
33 IRCCS Ospedale San Raffaele [Milan, Italy]
34 Stanford University
35 Mayo Clinic [Rochester]
36 Vanderbilt University [Nashville]
37 MSKCC - Memorial Sloan Kettering Cancer Center
38 Hammersmith Hospital NHS Imperial College Healthcare
39 KCH - King's College Hospital
40 University hospital of Zurich [Zurich]
41 University of Warwick [Coventry]
42 IRCCS San Raffaele Pisana - Istituto di Ricovero e Cura a Carattere Scientifico
43 University of Belgrade [Belgrade]
44 Emergency Institute for Cardiovascular Diseases “Prof. Dr. C.C. Iliescu” [Bucharest, Romania]
45 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
46 Royal Brompton Hospital
47 LH&CH - Liverpool Heart and Chest Hospital NHS Trust [UK]
48 La Paz University Hospital
49 Newcastle Upon Tyne Hospitals NHS Foundation Trust
50 Washington University School of Medicine in St. Louis

Abstract

This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
Fichier principal
Vignette du fichier
nihms-1663326.pdf (621.46 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

inserm-03935208 , version 1 (11-01-2023)

Identifiers

Cite

Alexander R Lyon, Susan Dent, Susannah Stanway, Helena Earl, Christine Brezden‐masley, et al.. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure, 2021, 22 (11), pp.1945 - 1960. ⟨10.1002/ejhf.1920⟩. ⟨inserm-03935208⟩
19 View
66 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More